Study identifier:NIS-CBE-XXX-2014/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
REalWorld insights on the INitiation and treatment Duration of ticagrEloR & other oral antiplatelets in patients with acute coronary syndrome in Belgium/Luxembourg (REWINDER)
Treatment of Acute Coronary Syndrome (ACS).
N/A
No
ACS patients treated with OAP
All
430
Observational
18 Years - 150 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jan 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
ACS patients treated with OAP Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets | Drug: ACS patients treated with OAP Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets. |